Aequus Pharmaceuticals (AQS) AI Stock Analysis

14 Followers

Aequus Pharmaceuticals

(TSXV:AQS)

Select Model

Rating:44Neutral

Price Target:CAD 0.01▲(0.00% Upside)

Action:initiatedcoverage

Date:01/13/26

The overall stock score of 44 for Aequus Pharmaceuticals reflects significant financial distress as the primary concern, with persistent losses, negative equity, and weak cash flows overshadowing revenue growth. Technical indicators show stability but limited momentum, and valuation metrics highlight ongoing risks due to unprofitability.

Positive Factors

Revenue GrowthThe launch of ZIMED® PF has contributed to revenue growth, indicating successful product development and market acceptance, which can enhance long-term revenue streams.

Negative Factors

Financial InstabilityPersistent financial instability with declining revenues and negative net income can hinder the company's ability to invest in growth and sustain operations long-term.

Aequus Pharmaceuticals (AQS) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 663.17K
Dividend Yield: ―
Average Volume (3M): 10.00K
Price to Earnings (P/E): 3.1
Beta (1Y): -8.40
Revenue Growth: ―
EPS Growth: ―
Country: Canada
Employees: 12
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Aequus Pharmaceuticals Business Overview & Revenue Model

Company Description

Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company dedicated to advancing and commercializing therapeutic solutions. Its core operations span critical areas such as neurology, ophthalmology, and transplantation. The company...

How the Company Makes Money

Aequus makes money primarily by commercializing pharmaceutical products that it has acquired or in-licensed, generating revenue from product sales and/or commercialization-related payments under its licensing agreements. Key revenue streams can inclu...

Aequus Pharmaceuticals Financial Statement Overview

Summary

Aequus Pharmaceuticals shows significant financial challenges. While revenue growth of 41.4% is a positive sign, persistent unprofitability with a net profit margin of -372.7%, negative stockholders' equity of -6.45 million, and negative operating cash flow of -1.66 million highlight serious risks to sustainability and financial stability.

Income Statement

25Negative

Balance Sheet

15Very Negative

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Dec 2021	Mar 2021
Income Statement
Total Revenue	815.03K	584.24K	254.90K	1.38M	2.71M	2.59M
Gross Profit	433.33K	199.97K	143.66K	1.15M	2.69M	2.59M
EBITDA	-1.13M	-1.79M	-2.68M	-2.87M	-1.23M	-314.80K
Net Income	-1.64M	-2.18M	-2.96M	-3.21M	-1.81M	-1.05M
Balance Sheet
Total Assets	236.02K	800.28K	1.09M	1.69M	4.35M	3.13M
Cash, Cash Equivalents and Short-Term Investments	35.08K	50.24K	170.20K	294.67K	2.39M	1.72M
Total Debt	6.64M	6.61M	5.06M	782.92K	2.18M	2.32M
Total Liabilities	7.51M	7.26M	5.38M	3.07M	2.56M	2.56M
Stockholders Equity	-7.27M	-6.45M	-4.29M	-1.38M	1.79M	573.95K
Cash Flow
Free Cash Flow	-443.32K	-1.66M	-2.29M	-1.95M	-1.18M	-817.23K
Operating Cash Flow	-443.32K	-1.66M	-2.29M	-1.95M	-1.17M	-804.91K
Investing Cash Flow	44.85K	44.85K	0	0	-507.96K	-12.32K
Financing Cash Flow	389.47K	1.49M	2.21M	-189.19K	2.40M	2.05M

Aequus Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TSE:AQS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:MDP	60Neutral	CAD 166.87M	-52.10	-4.69%	―	2.62%	-337.50%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TSE:MPH	46Neutral	CAD 39.66M	-5.18	-54.73%	―	38.25%	-450.85%
TSE:TGIF	45Neutral	CAD 5.21M	4.69	-11.60%	―	-4.90%	―
TSE:AQS	44Neutral	CAD 663.17K	3.13	-2.92%	―	―	―
TSE:PHRX	41Neutral	CAD 671.07K	-0.93	37.95%	―	―	-62.50%

* General Sector Average

Performance Comparison

TSE:AQS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:AQS	Aequus Pharmaceuticals	0.01	0.00	0.00%
TSE:PHRX	Pharmadrug Inc.	0.01	-0.01	-50.00%
TSE:MPH	Medicure Inc	3.70	2.41	186.82%
TSE:MDP	Medexus Pharmaceuticals	5.43	2.73	101.11%
TSE:TGIF	1933 Industries, Inc.	0.01	0.00	0.00%

Aequus Pharmaceuticals Corporate Events

Regulatory Filings and ComplianceShareholder Meetings

Aequus Pharmaceuticals Clarifies Shareholder Meeting Details Amid Regulatory Disclosures

Neutral

Nov 13, 2025

Aequus Pharmaceuticals has provided additional information regarding its upcoming annual general and special meeting of shareholders, scheduled for November 21, 2025. The company clarified details about a potential share consolidation, stating it wil...

Regulatory Filings and ComplianceShareholder Meetings

Aequus Pharmaceuticals Updates Shareholders on Key Meeting Details

Neutral

Nov 12, 2025

Aequus Pharmaceuticals has provided additional information regarding its upcoming annual general and special meeting of shareholders, as requested by the Ontario Securities Commission. The company clarified details about a potential share consolidati...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Dec 30, 2025

Aequus Pharmaceuticals AI Stock Analysis